Pathalys Series B Funding Obtains $105M

In order to fund its clinical studies, submit a new drug application (NDA) to the FDA, and expedite preapproval commercialisation arrangements, Pathalys Pharma has raised $105 million in a Series B fundraising round.

Upacicalcet, a medication used to treat secondary hyperparathyroidism (SHPT) in patients receiving dialysis for chronic kidney disease (CKD), is the company’s flagship candidate.

Pathalys initiated two similar Phase III trials of upacicalcet earlier this year, with 375 patients enrolled in each study. The goal of the PATH research program is to evaluate upacicalcet’s effectiveness in reducing intact parathyroid hormone (iPTH) in patients with SHPT who are undergoing hemodialysate by at least 30%.

Pathalys’s CEO Neal Fowler stated: “Since our inception, Pathalys has made significant strides toward our goal of delivering a best-in-class treatment for those with end-stage kidney disease (ESKD), including the near completion of two Phase III clinical trials for upacicalcet.”

They continued: “We believe the continued expansion of our syndicate of prominent life science investors, with representative board members, is indicative of the fact that we are on the right path at Pathalys.”